Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma.
Jeff M MichalskiAnna J JanssL Gilbert VezinaKyle S SmithCatherine A BillupsPeter C BurgerLeanne M EmbryPatricia L CullenKristina K HardyScott L PomeroyJohnnie K BassStephanie M PerkinsThomas E MerchantPaul D ColteThomas J FitzGeraldTimothy N BoothJoel M CherlowKarin M MuraszkoJennifer HadleyRahul KumarYuanyuan HanNancy J TarbellMaryam FouladiIan F PollackRoger J PackerYimei LiAmar J GajjarPaul A NorthcottPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Reducing the radiation boost volume in average-risk MB is safe and does not compromise survival. Reducing CSI dose in young children with average-risk MB results in inferior outcomes, possibly in a subgroup-dependent manner, but is associated with better neurocognitive outcome. Molecularly informed patient selection warrants further exploration for children with MB to be considered for late-effect sparing approaches.